Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 50.19

+1.8%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (8225)	5/1/2003 8:19:22 AM
From: Icebrg	of 52153

>>P.S. They [i.e. NBIX] say anything about the ED drug? Its class has been bedeviled by side effects (nausea).>> No, not really. Just a statement that the scientists working on the project at Pharmacia appeared to be very enthusiastic about the project and its merits. But I suppose that comes with the job. If I caught it right there has been a recent presentation of some good-looking data, but I didn't manage to get the details on that. The initiation of a second proof-of-principle phase II trial seem to indicate that not everyone is yet fully convinced. It was a very nice "gesture" of Pfizer to provide the drug as well as additional funding. Perhaps they wanted to get the drug(s) (there was another one going back to Nastech) out of the way in view of the pending merger. When big elephants mate there is bound to be some collateral damage. I wonder what Lynch had to provide in exchange? I don't believe the drug came as the complete gift as it has been presented. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next